DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1958)

Schizophrenia | Access & Reimbursement | Detailed, Expanded Analysis Schizophrenia and Major Depressive Disorder (China)

Schizophrenia | Access & Reimbursement | Detailed, Expanded Analysis Schizophrenia and Major Depressive Disorder (China)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Schizophrenia and major depressive disorder (MDD) are disabling psychiatric conditions that are linked to a heavy economic and disease burden on society and patients as well as their caregivers. Antipsychotics (older typical or newer atypical antipsychotics) are the standard of care for schizophrenia, and they are also used among treatment-resistant MDD patients. In an overgenericized market of well-established, mostly reimbursed key agents, psychiatrists may be reluctant to switch to newer and more expensive treatment options. However, high unmet need remains for therapies with demonstrated efficacy for both conditions. In this Access & Reimbursement analysis, we discuss the current access landscape for antipsychotics in China, with a focus on atypical antipsychotics’ use in schizophrenia and MDD. In addition, we analyze the future uptake of emerging therapies (e.g., Sumitomo Dainippon’s Latuda) and pinpoint the levers and roadblocks to their success.

Table of contents

  • Detailed, Expanded Analysis Schizophrenia and Major Depressive Disorder (China)
    • Actionable Recommendations to Optimize Market Access
      • Optimizing Market Access Opportunity for New Antipsychotics for Schizophrenia and MDD in China
    • Successes and Stumbles
      • Successes Among Schizophrenia and MDD Therapies in China
      • Stumbles Among Schizophrenia and MDD Therapies in China
      • China: Reimbursement Successes and Stumbles
    • Key Stakeholders in the Road to Market Access
      • China
    • Key Market Access Roadblocks
      • Key Market Access Roadblocks for Antipsychotics for Schizophrenia and MDD in China
    • Reimbursement Dynamics
      • China: Reimbursement Dynamics for Antipsychotics for Schizophrenia and MDD
        • China: HTA Details and Implications for Drug Coverage
        • China: Drivers of Formulary Coverage
        • China: Reimbursement Details
        • China: Lessons Learned and Key Takeaways
        • China: Reimbursement Background
    • Pricing and Reimbursement, Policy, and Coverage: Impact on Prescribing
      • Prescriber Preferences for Current Antipsychotics for Schizophrenia
      • Prescriber Preferences for Current Antipsychotics for MDD
      • Impact of Payer Policy on Prescribing for Schizophrenia and MDD
      • Top Prescribing Drivers: Schizophrenia
      • Top Prescribing Drivers: MDD
      • Key Levers and Constraints on Current Therapies
    • Market Access Landscape for Emerging Therapies
      • Likely Impact of Emerging Therapies on the Treatment of Schizophrenia
      • Likely Impact of Emerging Therapies on the Treatment of MDD
      • Market Access Challenges for Emerging Therapies for Schizophrenia and MDD
      • China: Payer Opinion on Emerging Therapies for Schizophrenia and MDD
    • Methodology
      • Primary Research Design
      • Physician Demographics and Practice Setting
        • How many years have you practiced post-residency?
        • How many adult patients with the following conditions do you treat per month?
        • In what city is your practice located?
        • What type of hospital(s) do you practice at?
    • Appendix
      • Commercial Context
        • Epidemiology
        • Treatment Algorithm for Schizophrenia and MDD in China
        • Key Drugs for Schizophrenia
        • Price per Day of Treatment for Schizophrenia Drugs
        • Timeline of Launch of Key Atypical Antipsychotics for Schizophrenia
        • Emerging Therapies Profiles
      • Physician Survey Data
        • Medicine Rate Target in Psychiatrists' Hospitals
        • Effect of Medicine Rate on Antipsychotics Prescription
        • Reasons Medicine Rate Not Affecting Psychiatrists' Prescription
        • Reasons Medicine Rate Affecting Psychiatrists' Prescription
        • Reimbursement Rate for Selected Antipsychotics in China
        • Estimated Diagnosis Rate for Schizophrenia and MDD
        • Estimated Treatment Rate for Schizophrenia and MDD
        • Percentage of MDD Patients Who Fail to Receive Treatment Because of Lack of Trained Personnel and Equipment
        • Patient Share of Typical Antipsychotics Among Schizophrenia patients
        • Reasons to Prescribe Typical Antipsychotics to Schizophrenia Patients
        • Patient Share of Atypical Antipsychotics Among Schizophrenia patients
        • Brand Share of Selected Antipsychotics
        • Prescribing Drivers of Selected Atypical Antipsychotics for Patients with Schizophrenia
        • Prescribing Drivers of Clozapine for Patients with Schizophrenia
        • Prescribing Drivers of Olanzapine for Patients with Schizophrenia
        • Prescribing Drivers of Risperidone for Patients with Schizophrenia
        • Reasons to Prescribe More Atypical Antipsychotics than Typical Antipsychotics to Schizophrenia Patients
        • Cost, Budgetary, and Reimbursement Reasons for Schizophrenia Patients Not Receiving Depot Formulations
        • Reasons Schizophrenia Patients Forgo Treatment with Antipsychotics
        • Psychiatrists' Perception of Atypical Antipsychotics in the Treatment of Schizophrenia
        • Most-Preferred Antipsychotics for the Positive Symptoms of Schizophrenia
        • Most Used Antipsychotics for the Cognitive Symptoms of Schizophrenia
        • Most Used Antipsychotics for the Negative Symptoms of Schizophrenia
        • Drivers for Prescribing an Antipsychotic for the Treatment of Negative and Cognitive Symptoms of Schizophrenia
        • Physicians' Choice of Treatment for Schizophrenia Without Access Barriers
        • Physicians' Definition of Treatment-Resistant Depression
        • Most Used Drug Classes for Treatment-Resistant Depression
        • Line of Therapy of Adjunctive Treatment for Which Antipsychotic Is Most Commonly Introduced for Treatment-Resistant MDD Patients
        • Patient Shares for Atypical Antipsychotics for Treatment-Resistant Depression
        • Prescribing Drivers of Atypical Antipsychotics for Patients with MDD
        • Prescribing Drivers of Olanzapine for Patients with MDD
        • Use of ECT in Treatment-Resistant MDD Patients
        • Use of ECT in combination with Atypical Antipsychotics in Treatment-Resistant MDD Patients
        • Limitations on the Off-Label Use of Antipsychotics for Major Depressive Disorder
        • Drivers for Choosing an Antipsychotic for Treatment-Resistant Depression
        • Physicians' Choice of Antipsychotic Treatment for Major Depressive Disorder Without Access Barriers
        • Physicians' Perceptions on Prices of Emerging Atypical Antipsychotics in China
        • Physicians' Intentions to Prescribe Emerging Atypical Antipsychotics for Schizophrenia Patients Once Available
        • Physicians' Intentions to Prescribe Emerging Atypical Antipsychotics for MDD Patients Once Available (Off-Label Uses)
        • Symptoms Treatment of Schizophrenia Patients with Emerging Atypical Antipsychotics
        • Physicians' Intentions on the Use of Emerging Atypical Antipsychotics in Different Lines of Therapy for the Treatment of Schizophrenia Patients
        • Physicians' Perceptions on the Replacement of Existing Antipsychotics with Emerging Atypical Antipsychotics for Schizophrenia Patients by End of 2019
        • Likely Use of Other Antipsychotics as Adjunct Therapies to Emerging Atypical Antipsychotics
        • Physicians' Intentions on the Use of Emerging Atypical Antipsychotics in Different Lines of Therapy for the Treatment of MDD Patients
        • Physicians' Perceptions on the Replacement of Existing Antipsychotics with Emerging Atypical Antipsychotics for MDD Patients by the End of 2019

Already a Client? Log in to access this report.

  • Pub Date: September 2016
  • Author(s): Michael Yeung, MSc
  • Based in DRG’s Hong Kong office, Michael analyses the evolving market access landscape in the Asia-Pacific region, including Australia, China, Japan, South Korea, The Philippines, and Taiwan. Michael is also responsible for market research and sales forecast in China among key therapeutic areas including diabetes. Michael previously worked as a health economics and outcome research consultant in Tokyo. Michael completed his Master degree in International Health Policy at London School of Economics and has a degree in Biochemistry from Imperial College London.

Purchase Report

Recent reports:
You may also be interested in: